CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

NMPA ACCEPTS SECOND MARKETING AUTHORISATION APPLICATION FOR SEMAGLUTIDE INJECTION

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the second marketing authorisation application for Semaglutide Injection (the "**Product**") developed by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd., a subsidiary of the Company, has been accepted by the National Medical Products Administration (the "**NMPA**") of the People's Republic of China. The indication for this application is long-term weight management in overweight adults or obese patients, in conjunction with diet control and increased physical activity. Previously, the Product's marketing authorisation application for the indication of glycemic control in adults with type 2 diabetes was accepted by the NMPA in August 2025.

The Product is a semaglutide preparation produced through chemical synthesis and has been applied for as a Class 2.2 new drug under the registration classification of chemical drugs, which contains known active ingredients with new formulation process and has significant clinical advantages. The Product avoids immunogenic substances such as host-cell proteins introduced during the biological fermentation, while ensuring that impurity levels are not higher than that of semaglutide produced through recombinant DNA technology. The Product exerts its effects by binding to the GLP-1 receptor, and achieves comprehensive benefits, such as weight reduction, glycemic control, and cardiovascular and renal protection, through multiple mechanisms.

This application is based on a Phase III clinical trial. The results of this clinical trial showed that in non-diabetic obese adult subjects, the Product significantly reduced body weight and waist circumference and improved blood glucose, lipid and liver enzyme levels; compared with semaglutide developed by Novo Nordisk, its efficacy was highly consistent, its safety profile was similar, and it was well-tolerated with a slightly lower incidence of adverse events. Based on its advantages in efficacy, safety and formulation, the Product possesses clear clinical application value.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 8 December 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping and Mr. QU Zhiyong as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.